GOSS vs. NRIX, VIR, ELVN, NTLA, ADPT, XNCR, RCUS, GYRE, COLL, and RCKT
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Enliven Therapeutics (ELVN), Intellia Therapeutics (NTLA), Adaptive Biotechnologies (ADPT), Xencor (XNCR), Arcus Biosciences (RCUS), Gyre Therapeutics (GYRE), Collegium Pharmaceutical (COLL), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs.
Nurix Therapeutics (NASDAQ:NRIX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
Gossamer Bio has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -354.85%. Nurix Therapeutics' return on equity of -53.65% beat Gossamer Bio's return on equity.
In the previous week, Gossamer Bio had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 13 mentions for Gossamer Bio and 8 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.61 beat Gossamer Bio's score of 0.60 indicating that Nurix Therapeutics is being referred to more favorably in the media.
Nurix Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.
Nurix Therapeutics currently has a consensus price target of $31.81, suggesting a potential upside of 134.09%. Gossamer Bio has a consensus price target of $9.20, suggesting a potential upside of 534.48%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Nurix Therapeutics.
Gossamer Bio has higher revenue and earnings than Nurix Therapeutics. Gossamer Bio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
81.2% of Gossamer Bio shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Gossamer Bio received 72 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 79.41% of users gave Nurix Therapeutics an outperform vote while only 66.52% of users gave Gossamer Bio an outperform vote.
Summary
Gossamer Bio beats Nurix Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 3/17/2025 by MarketBeat.com Staff
Free GOSS Stock Alerts